NYSE:ZYME

Zymeworks Competitors

$28.46
-2.54 (-8.19 %)
(As of 04/12/2021 04:15 PM ET)
Add
Compare
Today's Range
$28.19
Now: $28.46
$30.93
50-Day Range
$29.83
MA: $34.51
$41.14
52-Week Range
$28.02
Now: $28.46
$59.03
Volume571,473 shs
Average Volume525,258 shs
Market Capitalization$1.31 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.75

Competitors

Zymeworks (NYSE:ZYME) Vs. SRPT, ALLK, BPMC, PRGO, SDGR, and GLPG

Should you be buying ZYME stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Zymeworks, including Sarepta Therapeutics (SRPT), Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), Schrödinger (SDGR), and Galapagos (GLPG).

Zymeworks (NYSE:ZYME) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Risk & Volatility

Zymeworks has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.

Profitability

This table compares Zymeworks and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zymeworks-569.13%-44.06%-34.36%
Sarepta Therapeutics-121.30%-61.62%-23.02%

Analyst Recommendations

This is a breakdown of recent ratings for Zymeworks and Sarepta Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zymeworks03712.82
Sarepta Therapeutics191202.50

Zymeworks presently has a consensus price target of $51.50, suggesting a potential upside of 81.02%. Sarepta Therapeutics has a consensus price target of $150.4762, suggesting a potential upside of 116.89%. Given Sarepta Therapeutics' higher probable upside, analysts clearly believe Sarepta Therapeutics is more favorable than Zymeworks.

Institutional & Insider Ownership

75.1% of Zymeworks shares are held by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are held by institutional investors. 4.2% of Zymeworks shares are held by company insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Zymeworks and Sarepta Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zymeworks$29.54 million44.48$-145,440,000.00($3.83)-7.43
Sarepta Therapeutics$380.83 million14.47$-715,080,000.00($9.71)-7.15

Zymeworks has higher earnings, but lower revenue than Sarepta Therapeutics. Zymeworks is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Sarepta Therapeutics beats Zymeworks on 8 of the 15 factors compared between the two stocks.

Zymeworks (NYSE:ZYME) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Risk & Volatility

Zymeworks has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Profitability

This table compares Zymeworks and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zymeworks-569.13%-44.06%-34.36%
AllakosN/A-29.18%-27.70%

Analyst Recommendations

This is a breakdown of recent ratings for Zymeworks and Allakos, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zymeworks03712.82
Allakos00403.00

Zymeworks presently has a consensus price target of $51.50, suggesting a potential upside of 81.02%. Allakos has a consensus price target of $181.50, suggesting a potential upside of 73.95%. Given Zymeworks' higher probable upside, research analysts clearly believe Zymeworks is more favorable than Allakos.

Institutional & Insider Ownership

75.1% of Zymeworks shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 4.2% of Zymeworks shares are held by company insiders. Comparatively, 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Zymeworks and Allakos' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zymeworks$29.54 million44.48$-145,440,000.00($3.83)-7.43
AllakosN/AN/A$-85,370,000.00($1.89)-55.21

Allakos has lower revenue, but higher earnings than Zymeworks. Allakos is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Summary

Allakos beats Zymeworks on 8 of the 14 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Blueprint Medicines and Zymeworks, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06712.64
Zymeworks03712.82

Blueprint Medicines presently has a consensus price target of $111.00, indicating a potential upside of 19.87%. Zymeworks has a consensus price target of $51.50, indicating a potential upside of 81.02%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts plainly believe Zymeworks is more favorable than Blueprint Medicines.

Volatility & Risk

Blueprint Medicines has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.

Institutional and Insider Ownership

75.1% of Zymeworks shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by company insiders. Comparatively, 4.2% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Blueprint Medicines and Zymeworks' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Zymeworks-569.13%-44.06%-34.36%

Earnings and Valuation

This table compares Blueprint Medicines and Zymeworks' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million80.69$-347,690,000.00($7.27)-12.74
Zymeworks$29.54 million44.48$-145,440,000.00($3.83)-7.43

Zymeworks has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Summary

Blueprint Medicines beats Zymeworks on 7 of the 13 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Perrigo and Zymeworks, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Perrigo04102.20
Zymeworks03712.82

Perrigo presently has a consensus price target of $52.00, indicating a potential upside of 28.43%. Zymeworks has a consensus price target of $51.50, indicating a potential upside of 81.02%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts plainly believe Zymeworks is more favorable than Perrigo.

Volatility & Risk

Perrigo has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.

Institutional and Insider Ownership

82.7% of Perrigo shares are owned by institutional investors. Comparatively, 75.1% of Zymeworks shares are owned by institutional investors. 0.3% of Perrigo shares are owned by company insiders. Comparatively, 4.2% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Perrigo and Zymeworks' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Perrigo-0.13%9.78%4.92%
Zymeworks-569.13%-44.06%-34.36%

Earnings and Valuation

This table compares Perrigo and Zymeworks' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.84 billion1.12$146.10 million$4.0310.05
Zymeworks$29.54 million44.48$-145,440,000.00($3.83)-7.43

Perrigo has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Summary

Perrigo beats Zymeworks on 8 of the 15 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Schrödinger and Zymeworks, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Zymeworks03712.82

Schrödinger presently has a consensus price target of $85.50, indicating a potential upside of 15.87%. Zymeworks has a consensus price target of $51.50, indicating a potential upside of 81.02%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts plainly believe Zymeworks is more favorable than Schrödinger.

Institutional and Insider Ownership

41.3% of Schrödinger shares are owned by institutional investors. Comparatively, 75.1% of Zymeworks shares are owned by institutional investors. 4.2% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Schrödinger and Zymeworks' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Zymeworks-569.13%-44.06%-34.36%

Earnings and Valuation

This table compares Schrödinger and Zymeworks' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million60.39$-24,570,000.00N/AN/A
Zymeworks$29.54 million44.48$-145,440,000.00($3.83)-7.43

Schrödinger has higher revenue and earnings than Zymeworks.

Galapagos (NASDAQ:GLPG) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Volatility & Risk

Galapagos has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.

Profitability

This table compares Galapagos and Zymeworks' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos-70.67%-11.78%-5.58%
Zymeworks-569.13%-44.06%-34.36%

Institutional and Insider Ownership

11.2% of Galapagos shares are owned by institutional investors. Comparatively, 75.1% of Zymeworks shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 4.2% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Galapagos and Zymeworks' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion5.05$167.83 million$5.4614.17
Zymeworks$29.54 million44.48$-145,440,000.00($3.83)-7.43

Galapagos has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Galapagos and Zymeworks, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos211402.12
Zymeworks03712.82

Galapagos presently has a consensus price target of $143.7273, indicating a potential upside of 85.79%. Zymeworks has a consensus price target of $51.50, indicating a potential upside of 81.02%. Given Galapagos' higher probable upside, equities analysts plainly believe Galapagos is more favorable than Zymeworks.

Summary

Galapagos beats Zymeworks on 8 of the 15 factors compared between the two stocks.


Zymeworks Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$69.38-1.7%$5.60 billion$380.83 million-8.87
Allakos logo
ALLK
Allakos
1.7$104.34-0.6%$5.58 billionN/A-38.08
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.60-1.7%$5.46 billion$66.51 million17.08
Perrigo logo
PRGO
Perrigo
2.5$40.52-0.0%$5.41 billion$4.84 billion-675.22
Schrödinger logo
SDGR
Schrödinger
1.5$73.79-0.1%$5.17 billion$85.54 million0.00Insider Selling
Galapagos logo
GLPG
Galapagos
1.3$77.36-0.6%$5.10 billion$1.00 billion-11.72Analyst Report
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$55.20-2.4%$4.68 billionN/A0.00
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.68-2.6%$4.47 billion$6.87 million-7.22Analyst Report
Analyst Revision
News Coverage
Gap Up
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.77-1.9%$4.31 billionN/A-5.77Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.33-0.3%$4.26 billion$204.89 million-36.66Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$75.86-2.0%$4.12 billion$1.11 billion24.39
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$64.80-2.3%$4.00 billion$806.43 million-9.18Unusual Options Activity
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$74.88-5.4%$3.87 billionN/A-21.33News Coverage
LEGN
Legend Biotech
1.2$27.75-2.5%$3.76 billion$64.39 million0.00Gap Up
I-Mab logo
IMAB
I-Mab
1.4$47.75-8.2%$3.72 billion$4.31 million-1.65Gap Up
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.24-1.0%$3.64 billion$117.91 million-10.60
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.28-6.8%$3.44 billion$36.13 million-69.07
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.69-0.3%$3.40 billion$114.62 million-7.54Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.14-1.0%$3.35 billion$306.98 million-6.74
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60
Insmed logo
INSM
Insmed
1.2$30.83-2.8%$3.27 billion$136.47 million-11.86
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.44-0.2%$3.26 billion$339.08 million-11.88
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$85.76-3.1%$3.20 billion$26.52 million-7.56
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.72-3.7%$3.16 billionN/A-56.08Gap Up
Arvinas logo
ARVN
Arvinas
1.5$60.51-4.9%$3.10 billion$42.98 million-23.64
Alkermes logo
ALKS
Alkermes
1.4$18.80-1.2%$3.03 billion$1.17 billion-40.87Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.04-0.3%$2.99 billion$421.03 million23.96Analyst Report
Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.09-1.2%$2.94 billion$80.43 million105.20
Organogenesis logo
ORGO
Organogenesis
1.0$22.96-0.5%$2.92 billion$260.98 million-382.67Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.06-3.0%$2.80 billion$901.90 million-22.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.59-0.3%$2.79 billion$644.77 million-10.36
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.44-1.1%$2.66 billion$306.49 million25.21
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.71-0.1%$2.56 billion$60,000.00-9.85News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.86-10.2%$2.56 billionN/A0.00
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.88-5.9%$2.55 billion$120.28 million-146.34
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.00-1.9%$2.53 billion$2.11 million-8.66
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.04-0.5%$2.52 billion$25 million-8.81
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.92-3.7%$2.43 billionN/A-22.48
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.29-1.1%$2.43 billion$182.24 million-8.08
Cryoport logo
CYRX
Cryoport
1.9$51.64-1.3%$2.38 billion$33.94 million-89.03Insider Selling
Xencor logo
XNCR
Xencor
1.2$39.57-2.3%$2.35 billion$156.70 million-28.26News Coverage
Amarin logo
AMRN
Amarin
1.6$5.85-1.4%$2.33 billion$429.76 million-116.98
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$30.49-2.7%$2.22 billion$15 million-15.96
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.30-1.2%$2.18 billion$963.01 million13.76
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$62.13-10.2%$2.10 billionN/A-26.44
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.95-0.6%$2.01 billion$410,000.00-6.08
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.18-0.3%$1.99 billion$23.90 million-16.26Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$51.74-2.4%$1.98 billionN/A-19.23
MORF
Morphic
1.3$57.99-2.3%$1.93 billion$16.98 million-37.17Insider Selling
News Coverage
Gap Up
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.